Involvement of Aquaporin 3 in *Helicobacter pylori*-Related Gastric Diseases

Gang Wang1, Fei Gao1, Weiming Zhang2, Jia Chen1, Tao Wang1, Guoxin Zhang3, Lizong Shen1*

1 Division of Gastrointestinal Surgery, Department of General Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China, 2 Department of Pathology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China, 3 Department of Gastroenterology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China

Abstract

**Background:** Gastric cancer is one of the most common and lethal malignant cancers worldwide, and numerous epidemiological studies have demonstrated that *Helicobacter pylori* (*H. pylori*) infection plays a key role in the development of gastric carcinomas. Our previous studies showed that aquaporin 3 (AQP3) is overexpressed in gastric carcinoma and promotes the migration and proliferation of human gastric carcinoma cells, suggesting that AQP3 may be a potentially important determinant of gastric carcinoma. However, the role of AQP3 in *H. pylori* carcinogenesis is unknown.

**Methods:** The AQP3 protein and *H. pylori* were detected in human gastric tissues by immunohistochemistry and modified Giemsa staining respectively. AQP3 knockdown was obtained by small interfering (si) RNA. Western blot assays and RT-PCR were used to evaluate the change of AQP3 in the human gastric cancer AGS and SGC7901 cell lines after co-culture with *H. pylori*. Sprague Dawley rats were orally inoculated with *H. pylori* to establish a rat model colonized by *H. pylori*.

**Results:** The present study found that AQP3 expression correlated with *H. pylori* infection status in gastric cancer tissues and corresponding normal mucosa, and *H. pylori* co-culture upregulated AQP3 expression in human gastric adenocarcinoma cells *in vitro* via the extracellular signal-regulated kinase signaling pathway. *H. pylori* infection also increased AQP3 expression in gastric mucosa colonized by *H. pylori* in a Sprague Dawley rat model.

**Conclusions:** These findings provide further information to understand the mechanism of *H. pylori* carcinogenesis and a potential strategy for the treatment of *H. pylori*-associated gastric carcinoma.

Introduction

Gastric carcinoma remains one of the most common and lethal malignancies worldwide, with approximately 1 million cases diagnosed annually, accounting for 738,000 deaths in 2008. Over 70% of the new cases and deaths occur in developing countries [1]. Numerous epidemiological studies have indicated that *Helicobacter pylori* (*H. pylori*) plays a key role in the development of both intestinal-type and diffuse-type gastric carcinomas, especially in the distal portion of the stomach [2–4]. Regional variations in the incidence partially reflect differences in the prevalence of *H. pylori* infection [5,6]. Stomach cancer rates have decreased substantially in most parts of the world [7], partially because of reductions of chronic *H. pylori* infection in these areas [8–10]. *H. pylori* has been demonstrated to promote tumorigenesis [11]. *H. pylori* infection is defined as a definite or Class I carcinogen in the human stomach by the World Health Organization [3]. *H. pylori* strains produce various toxins that enable the bacteria to cause host cell damage, including cytotoxin-associated gene A (CagA) and vacuolating cytotoxin (VacA) [12]. Recent studies showed that infection with CagA-positive *H. pylori* plays an essential role in the development of gastric carcinoma. The cagA-encoded CagA protein is delivered into gastric epithelial cells via the bacterial type IV secretion system [2]. Moreover, CagA interacts with many signaling molecules and elicits a series of cellular events. Changes related to cell morphology, cell scattering, cell proliferation, and intercellular tight junctions have also been identified [13]. *H. pylori* infection may cause a combination of increased endogenous DNA damage, decreased repair activity, and the induction of mutations in mitochondrial DNA that generate genetic instability in gastric cells and promote gastric carcinogenesis [14].

Aquaporins (AQPs) are a family of small, integral membrane proteins that transport water and, in some cases, water and glycerol (“aquaglyceroporins”) [15,16]. Aquaporins are involved in transepithelial fluid transport, as it occurs in the urinary concentrating mechanism and glandular fluid secretion. Accumulating evidence further implicates AQPs in cell migration and proliferation, adding AQPs to an expanding list of effectors in tumor biology [17]. We showed previously that human gastric
carcinoma tissues expressed higher levels of AQP3 than normal mucosa, and AQP3 expression was associated with histological classification, lymph node metastasis, and lymphovascular invasion [18,19], suggesting that AQP3 may play an important role in human gastric cancer. In addition, we showed that AQP3 promotes the migration and proliferation of human gastric carcinoma AGS and SGC7901 cells, suggesting that AQP3 may be a potentially important determinant of tumor growth and the spread of human gastric carcinoma [20,21].

However, the role of AQP3 in *H. pylori* carcinogenesis remains unclear. Based on our previous findings, we speculated that AQP3 may play an important role in *H. pylori*-related gastric diseases. In the present study, we investigated the relationship between the expression of AQP3 in gastric carcinoma tissues or corresponding normal mucosa and *H. pylori* infection status, and the effects of *H. pylori* on AQP3 expression in gastric cells were examined in *vitro* and in *vivo*. We found that AQP3 expression in gastric cancer tissues correlated with *H. pylori* infection status, and *H. pylori* upregulated AQP3 expression in human gastric adenocarcinoma cells in *vitro* via the extracellular signal-regulated kinase (ERK) signaling pathway, confirmed by experimental gastric helicobacter infection in rats. These findings provide further information to understand the mechanism of *H. pylori* carcinogenesis and a potential strategy for the treatment of *H. pylori*-associated gastric carcinoma.

**Materials and Methods**

**Human Gastric Tissue Specimens**

Human gastric tumor tissue specimens were randomly obtained from 89 gastric adenocarcinoma patients (median age, 56 years; range, 35–75 years; 58 males, 31 females) between June 2007 and September 2008 at the Department of General Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, China. All of the patients were diagnosed pathologically according to the American Joint Committee on Cancer criteria. Samples of tumor and corresponding non-cancerous tissue from all of the patients were collected immediately after resection and snap-frozen in liquid nitrogen. Based on the Lauren classification, 54 cases were categorized as stage I, 19 cases were stage II, 13 cases were stage III, and 35 cases were diffuse gastric cancer. The tumors of 15, 26, and 48 cases were located in the upper third, middle third, and lower third of the stomach, respectively.

**Determination of H. pylori infection status**

Informed consent was obtained from all of the patients. *H. pylori* infection status was determined by modified Giemsa staining. *H. pylori* + and − were defined as + when positive staining was observed in at least 10% of cells and − when no staining was observed in any cells.

**Western Blot Assays**

Cellular or tissue extracts were prepared with ice-cold radio-immunoprecipitation assay buffer that contained 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM ethylenediaminetetraacetic acid, 0.25% sodium deoxycholate, 1 mM NaF, 10 μM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and a cocktail of protease inhibitors (10 μg/ml leupeptin, 10 μg/ml aprotinin, and 1 μg/ml pepstatin). The concentrations were determined by the bicinchoninic acid protein assay. Immunoblotting was performed as previously described [21], and the following antibodies were used for the procedure: anti-AQP3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-ERK and anti-ERK antibody (Cell Signaling Technology, Beverly, MA), and anti-β-actin antibody (Santa Cruz Biotechnology). Protein bands were detected using an enhanced chemiluminescence (ECL) detection system according to the manufacturer’s instructions and visualized by Hyperfilm. Protein densitometric analysis was performed with normalization against β-actin.

**Real-time Quantitative Polymerase Chain Reaction (RT-qPCR)**

Total RNA from the cells was prepared with Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol under RNase-free condition. After cDNA was synthesized with a two-step reverse transcription reaction kit (TAKARA, Dalian, China), quantitative PCR was carried out on an Applied Biosystems 7500 Real-time PCR System using SYBR Premix Ex Taq Kit (Applied Biosystems, USA) in a 96-well reaction plates, following the manufacturer’s instructions. β-actin was amplified to serve as a reference for each sample and the observed AQP3 expression level was normalized to the level of β-actin. The following pairs of primers were AQP3, forward primer corresponding to nucleotides 5’-CACAGCGCCGCATCTTTGTGA-3’ and reverse primer complimentary to nucleotides 5’-TGGCGGAGCACACACAC-
GATA-3; β-actin, forward primer 5′-TCACCCA-CACTGTGCCTCAGA-3′ and reverse primer 5′-CAGCGGAACCGCTCATTGCCAATGG-3′. All procedures were performed in triplicate.

In vitro Migration (scratch) Assay and Cell Proliferation Assay

In vitro migration was assayed as previously described [20]. The representative images of the scratched areas under each condition were photographed. To estimate the relative migration of the cells, the unclosed cell-free areas from five prints under each condition were excised. Migration was quantified as the “average gap” (average gap, the percentage of the unclosed cell-free areas according to initial scratch distance). The polylysine alone at 0 h was considered 100% of the average gap. For the cell migration experiment, at least 50 cell migration distances were counted for one experiment. Cell proliferation was analyzed using a WST-8 Cell Counting Kit-8 (CCK-8; Sigma) according to the manufac-

Figure 1. AQP3 expression and H. pylori detection in human gastric cancer by IHC and Giemsa staining. Strong positive (+++) AQP3 immunoreactivity was identified in moderately differentiated adenocarcinoma (E) with H. pylori detection in the gastric glands (A, yellow arrow), which was stronger than in the corresponding non-cancerous mucosa (+) (C). However, weak positive AQP3 reactivity (+) was observed in well-differentiated adenocarcinoma (F) with negative H. pylori detection (B), and AQP3 reactivity in the corresponding normal mucosa was weaker (D). doi:10.1371/journal.pone.0049104.g001
Establishment of a Sprague Dawley Rat Model Colonized by H. pylori

Thirty Sprague Dawley rats (Vitalriver, Nanjing, China; weight, 180±20 g) were randomly divided into two groups: H. pylori treatment group and control group, each containing fifteen rats. Rats in the H. pylori treatment group were orally inoculated with H. pylori 26695 resuspended in 4 ml phosphate-buffered saline (PBS) that contained 5×10⁹ CFU/ml. H. pylori treatment was performed twice per week and lasted 4 consecutive weeks. Before inoculation, these rats were fasted for 24 h and slowly pretreated with 3 ml of 5% NaHCO₃ intragastrically 30 min before inoculation. The animals in the control group were administered PBS accordingly. Three months after inoculation, gastric mucous occlusion. The animals in the control group were administered PBS accordingly. Three months after inoculation, gastric mucous tissues in the antrum were harvested for further assay, including pathological diagnosis with hematoxylin-eosin staining using the Visual Analog Scale of the Updated Sydney System [24], modified Giemsa staining with cultivation and rapid urease test for H. pylori detection, and Western blot to assess AQP3 expression.

Statistical Analysis

The data are expressed as mean± standard error. In the experiments that involved protein expression, the values were representative of at least three independent experiments. Clinico-pathological findings were compared using an unpaired t-test or the Pearson χ² test. The statistical analysis of the data between the control and treated groups was performed using analysis of variance (ANOVA). Values of p<0.05 were considered statistically significant.

Results

AQP3 Expression in Gastric Cancer Tissues Correlates with H. pylori Infection Status

AQP3 protein expression was evaluated by IHC and H. pylori infection by modified Giemsa staining in 89 human gastric tumor tissue specimens and corresponding non-cancerous mucosa in the antrum. The prevalence of H. pylori in these patients was 59.6% (53/89; Table 1). As we reported previously, AQP3 protein expression in gastric cancer tissues was higher than in corresponding normal tissues [19], although weak to moderate positive AQP3 reactivity was found in the non-cancerous mucosa (Fig. 1). H. pylori colonized the lumen of the gastric glands in 51 cases (57.3%) (Fig. 1). However, AQP3 reactivity in both normal gastric mucosa and gastric cancer tissues was markedly associated with H. pylori infection (p=0.000; Table 1), indicating that AQP3 may be involved in H. pylori infection-related gastric diseases.

H. pylori Upregulates AQP3 Expression in Human Gastric Adenocarcinoma Cells in vitro

In vitro experiments were performed to investigate the effects of H. pylori infection on AQP3 expression in human gastric carcinoma cells. We co-cultured SGC7901 and AGS gastric carcinoma cells with H. pylori. Immunoblotting assays with anti-AQP3 antibody showed that H. pylori infection dose- and time-dependently increased the protein levels of AQP3 in both cell lines (Fig. 2A and 2C). Furthermore, AQP3 expression increased approximately two- to three-fold in AGS cells and two- to four-fold in SGC7901 cells in the H. pylori co-culture over a range of 1:50 to 1:100 (cells to bacteria). AQP3 expression also increased over time by 1.5- to two-fold at 12 h to over three- to four-fold at 24 h posttreatment with H. pylori (1:50) in both cell lines.

To investigate whether H. pylori upregulates AQP3 expression at the transcriptional or posttranscriptional level, RT-qPCR assays were performed to examine the mRNA transcript levels of AQP3 in AGS and SGC7901 cells. We found that H. pylori significantly increased the mRNA transcript levels of AQP3 in both cell lines (Fig. 2B and 2D).

H. pylori Infection Induces Migration and Proliferation of Gastric Cancer Cells via AQP3

As shown in many studies, H. pylori infection promotes the migration and proliferation of gastric epithelial cells, which is thought to be critical characteristic of H. pylori-associated gastric cancer [25,26]. Our previous study [20] prompted us to investigate whether H. pylori regulates the promotion and migration of gastric mucosa cells via AQP3. We transfected the human gastric cancer cell lines with siRNA against AQP3 or scrambled siRNA. Immunoblotting assays showed that siRNA against AQP3 reduced AQP3 expression by approximately two-thirds in both AGS and SGC7901 cells. Additionally, AQP3 knockdown significantly attenuated the H. pylori-induced increase in AQP3 expression in both AGS and SGC7901 cells (Fig. 3A). Accordingly, AQP3 knockdown inhibited the H. pylori-induced increase in gastric cell proliferation and migration (Fig. 3B and 3C). These data suggest that AQP3 is involved in H. pylori-induced changes in cell behavior.

The ERK Signaling Pathway is Involved in H. pylori-regulated AQP3 Expression in Human Gastric Cancer Cells

The activation of ERK signaling pathway is involved in cell migration and proliferation [27], and our previous study showed that AQP3 expression in gastric cells is regulated mainly via the ERK signaling pathway [20,21]. We further investigated whether the ERK signaling pathway is involved in H. pylori-regulated AQP3 expression in human gastric cancer. Immunoblotting studies using anti-phospho-ERK antibody revealed the phosphorylation of ERK in both AGS and SGC7901 cells at 2 h

| Variables                  | AQP3 | H. pylori positive | H. pylori negative | X²  | p       |
|----------------------------|------|-------------------|--------------------|-----|---------|
| Normal gastric mucosa      | ±    | 11                | 24                 | 18.94| 0.001   |
|                           | +    | 42                | 12                 |     |         |
| Gastric cancer tissues     | +    | 8                 | 21                 | 18.25| 0.001   |
|                           | 2++~3+| 45               | 15                 |     |         |

doi:10.1371/journal.pone.0049104.t001

Table 1. AQP3 expression is associated with H. pylori infection status.
human gastric adenocarcinoma cells was analyzed after 12 h and quantified as normalization against independent experiments.

(C and D). The data are expressed as the mean ± SEM of three experiments.

\( p<0.05 \), compared with untreated (UNTR) group.

doi:10.1371/journal.pone.0049104.g002

Figure 2. H. pylori treatment upregulated AQP3 expression in human gastric adenocarcinoma cells in vitro. Cultured AGS and SGC7901 cells were treated with H. pylori (1:50), AQP3 protein and mRNA expression was analyzed by Western blot and RT-qPCR in (A) and (B) at different time points (12 and 24 h) and quantified with normalization against β-actin. The cells were also treated with various doses of H. pylori (1:50, 1:100), and AQP3 protein and mRNA expression was analyzed after 12 h and quantified as normalization against β-actin (C and D). The data are expressed as the mean ± SE of three independent experiments. \( p<0.05 \), compared with untreated (UNTR) group.

dot:10.1371/journal.pone.0049104.g002

posttreatment with H. pylori (1:100), which continued at this level for approximately 4 h and returned to baseline at 8 h posttreatment (Fig. 4A), which was consistent with other report [28]. U0126, a small-molecule inhibitor of mitogen-activated protein kinase (MAPK)/ERK, abrogated H. pylori-induced ERK phosphorylation (Fig. 4B). Furthermore, pretreatment with 10 μM U0126 for 2 h partially inhibited the H. pylori-induced increase in AQP3 expression (Fig. 4C). These data indicate that the ERK signaling pathway is involved in H. pylori-regulated AQP3 expression in human gastric carcinoma cells.

H. pylori Infection Upregulates AQP3 Expression in an Experimental Gastric Helicobacter Infection Rat Model

To further investigate the role of AQP3 in H. pylori-related gastric diseases, a Sprague Dawley rat model colonized by H. pylori was established. The gastric mucosa in the rats with H. pylori treatment showed moderate histological findings, including submucosal bleeding and mononuclear cell infiltration. No marked histological changes were found in the mucosa of the rats in the control group (Fig. 5A and 5B). Modified Giemsa staining revealed large numbers of bacteria that colonized the lumen of the gastric glands in the H. pylori-treated groups, and no bacterium was found in the control groups (Fig. 5C and 5D). Furthermore, cultivation of rat gastric mucosa on Columbia agar plates showed that H. pylori colony formed in the H. pylori-treated groups and no colony in the control groups, which were confirmed by the rapid urease test after colony formation. These results indicated that the experimental gastric H. pylori infection model was successfully established. Importantly, AQP3 expression in the gastric mucosa of the H. pylori-treated group was stronger than in the control group, indicating that AQP3 is involved in H. pylori infection (Fig. 5E–G).

Discussion

H. pylori is an important pathogen involved in gastritis, peptic ulcers, gastric carcinoma, and primary gastric lymphoma. The prevalence of H. pylori infection differs significantly among countries, with a higher prevalence in developing countries compared with developed countries. Shi et al. [6] reported that H. pylori was detected in 851 individuals among 1371 subjects (62%) in a Chinese prospective epidemiologic survey of H. pylori infection, and the prevalence reached a peak at an age of 30–40 years. Although H. pylori infection rates have decreased in the general Chinese population during recent years, the prevalence of H. pylori infection among both children and adults remains significantly higher in areas with a high incidence of gastric cancer in China compared with areas with a low incidence of gastric cancer [29]. Gastric carcinoma is the second most frequently diagnosed cancer and third leading cause of cancer death in China, with an estimated 464,439 new cases and 352,315 cancer deaths in 2008 [30], accounting for 42% of all gastric cancer cases worldwide.

Several recent clinical studies have reported an association between H. pylori infection and gastric carcinogenesis [31–36]. Umemura et al. [31] found that gastric cancer developed in 36 of 1246 H. pylori-infected patients but none of the 280 uninfected patients in a prospective study that involved 1526 Japanese patients with peptic ulcers, gastric hyperplasia, and non-ulcer dyspepsia. This seminal study offered compelling evidence that H. pylori infection is associated with the development of both intestinal and diffuse gastric cancers. The role of H. pylori in the development of gastric cancer has also been demonstrated in clinical studies conducted in Chinese. The majority of epidemiologic studies that examined the association between H. pylori infection and gastric cancer in China were retrospective case-control studies. All 11 case-control studies included in a 2001 meta-analysis showed a positive association [32]. A recent hospital-based case-control study conducted in Taiwan also showed that H. pylori infection...
AQP3 in *H. pylori*-Related Gastric Diseases

A

![Images of western blot and bar graphs showing AQP3 expression levels and fold change in AGS and SGC7901 cells under different conditions.](Image)

B

![Images of histological sections showing cell morphology and gap formation in AGS and SGC7901 cells under different conditions.](Image)

C

![Images of bar graphs showing relative proliferation rates in AGS and SGC7901 cells under different conditions.](Image)
increased gastric adenocarcinoma risk, including cardia and non-cardia [33]. This positive association was also observed in two prospective cohort studies. Yuan et al. [34] reported that the odds ratio was 3.74 for individuals who were seropositive for *H. pylori* and followed for 5 or more years in a nested case-control study with a cohort of Shanghai residents. A prospective, nested case-control study in Linxian, one of the highest-incidence regions in China, found that *H. pylori* seropositivity was associated with an approximately two-fold increased risk of gastric cancer [35]. These results were confirmed by a 2007 case-cohort study, in which *H. pylori* was associated with a 1.6-fold increased risk of both cardia and non-cardia gastric adenocarcinomas [36].

Figure 3. *H. pylori* treatment promotes cell migration and proliferation via AQP3 in vitro. AQP3 siRNA abated the level of AQP3 in AGS and SGC7901 cells (A). AGS and SGC7901 cells were treated with or without AQP3 siRNA and scrambled siRNA, followed by treatment with *H. pylori* (1:100) for 24 h. AQP3 protein expression was analyzed by Western blot (A) with quantification normalized against β-actin or the untreated (UNTR) group. Cell migration was detected by in vitro migration (scratch) assays as described previously [20] and photographed at 24 h (B) to determine the average gap. Changes in cell proliferation in each group were detected by CCK-8 and are expressed as the fold change (C). The data are expressed as the mean ± SE of three independent experiments. *p<0.05, compared with untreated (UNTR) group. **p<0.05, compared with *H. pylori*-treated group.

doi:10.1371/journal.pone.0049104.g003

Figure 4. *H. pylori* treatment upregulates AQP3 expression in gastric adenocarcinoma cells via the ERK pathway. *H. pylori* treatment induced ERK activation in human gastric adenocarcinoma cells, which reached a peak at 2 h and continued at this level for approximately 4 h (A). AGS cells and SGC7901 cells were pretreated with various doses of the MAPK/ERK inhibitor U0126 (5, 10, and 20 μM) for 1.5 h, followed by *H. pylori* (1:100) for 4 h. ERK activation (pERK) was detected by Western blot (B) to determine the optimal dose of U0126. The cells were treated with *H. pylori* (1:100) with or without the MAPK/ERK inhibitor U0126 (10 μM) for 2 h, and AQP3 expression was analyzed by Western blot and quantified with normalization against β-actin (C). *p<0.05, compared with untreated (UNTR) group. **p<0.05, compared with *H. pylori*-treated group.

doi:10.1371/journal.pone.0049104.g004
AQP3 in \textit{H. pylori}-Related Gastric Diseases

\textbf{A}\hspace{1cm}\textbf{B}\hspace{1cm}\textbf{C}\hspace{1cm}\textbf{D}\hspace{1cm}\textbf{E}\hspace{1cm}\textbf{F}\hspace{1cm}\textbf{G}

\hspace{1cm}

\begin{tabular}{ccc}
\textbf{Rat} & \textbf{UNTR} & \textbf{H. Pylori} \\
\textbf{AQP3} & \hspace{1cm} & \\
\textbf{\(\beta\)-actin} & \hspace{1cm} & \\
\end{tabular}

\hspace{1cm}

\begin{tabular}{cc}
\textbf{AQP3 (fold change)} & \\
\textbf{SD Rat} & \# \\
\textbf{UNTR} & \hspace{1cm} \\
\textbf{H. Pylori} & \hspace{1cm} \\
\end{tabular}
The eradication of colonizing *H. pylori* decreases the risk of developing gastric cancer. A multicenter, open-label, randomized controlled trial followed 544 patients who underwent endoscopic resection of early gastric cancer, half of whom underwent eradication of colonizing *H. pylori* [37]. Eradication decreased the risk by approximately 65%, although these patients had already been diagnosed with early gastric cancer. To determine whether *H. pylori* eradication reduces the incidence of gastric cancer at the population level in high-risk areas in China, Wong et al. [38] conducted a randomized, placebo-controlled trial in subjects without precancerous lesions. Although the difference in the incidence of gastric cancer development between participants who received *H. pylori* eradication treatment and patients who received placebo for 7.5 years in a high-risk region of China was not significant, eradication of *H. pylori* significantly decreased the development of gastric cancer in the subgroup of *H. pylori* carriers without precancerous lesions. In the Shandong Intervention Trial, 2 weeks of antibiotic treatment for *H. pylori* reduced the prevalence of precancerous gastric lesions [39]. Recently, they reported that gastric cancer was diagnosed in 3.0% of subjects who received *H. pylori* treatment and 4.6% of subjects who received placebo (odds ratio = 0.61, 95% confidence interval = 0.38–0.96, *p* = 0.032) after a 14.7-year follow-up for gastric cancer [40].

Our previous studies indicated that AQP3 plays an important role in the tumor growth and spread of human gastric carcinoma [20]. However, whether AQP3 is involved in *H. pylori* infection-related gastric cancer is unknown, and no studies of which we are aware have investigated alterations in the expression of AQP3 in *H. pylori*-infected stomach mucosa [41]. In the present study, we found that *H. pylori* infection upregulated AQP3 expression in non-cancerous mucosa and gastric cancer tissues.

To investigate the effect of *H. pylori* infection on AQP3 and the role of AQP3 in *H. pylori* infection, we performed an *in vitro* experiment using gastric carcinoma cells co-cultured with *H. pylori*. *H. pylori* infection dose- and time-dependently increased the protein levels and transcription of AQP3, indicating that AQP3 may be involved in *H. pylori*-infected gastric diseases. *H. pylori* infection promoted the proliferation and migration of gastric epithelial cells, which may contribute to the carcinogenic process. RNAi assays in this study showed that knockdown of AQP3 attenuated the *H. pylori*-induced proliferation and migration of cancer cells. These data suggest that AQP3 is involved in *H. pylori*-induced changes in cell behavior. Our previous study found that AQP3 expression in gastric cells is regulated mainly via the ERK signaling pathway. We provide further evidence that the ERK signaling pathway is also involved in *H. pylori*-regulated AQP3 expression in human gastric carcinoma cells.

Furthermore, we established a Sprague Dawley rat model colonized by *H. pylori*. We did not induce gastric cancer in this model, but the animals treated with *H. pylori* presented moderate gastritis. AQP3 expression in the gastric mucosa of the *H. pylori* treatment group was higher than in the control group, directly indicating that AQP3 is involved in *H. pylori* infection.

In summary, although the present study is preliminary, our results demonstrated that AQP3 is involved in *H. pylori* infection-related diseases, especially *H. pylori*-related gastric carcinogenesis. However, we used CagA-positive *H. pylori*, *H. pylori* 26695, to treat gastric cancer cells and animals without using CagA-negative one as a control. Therefore, further studies that investigate whether *H. pylori* infection upregulates AQP3 expression in gastric cancer cells via CagA protein during carcinogenesis are warranted. If a gastric cancer model induced by *H. pylori* is established, the results may be more convincing. However, the present findings provide further information to understand the mechanism of *H. pylori* carcinogenesis and a potential strategy for the treatment of *H. pylori*-associated gastric carcinoma.

**Author Contributions**

Conceived and designed the experiments: LS. Performed the experiments: GW FG WZ. Analyzed the data: GZ JC TW. Wrote the paper: LS.

**References**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Hatakeyama M (2009) *Helicobacter pylori* and gastric carcinogenesis. J Gastroenterol 44: 239–248.
3. Konturek PC, Konturek SJ, Brzozowski T (2009) *Helicobacter pylori* infection in gastric cancerogenesis. J Physiol Pharmacol 60: 3–21.
4. Shin CM, Kim N, Yang HJ, Cho SI, Lee HS, et al. (2010) Stomach cancer risk and gastric cancerogenesis. J Physiol Pharmacol 60: 3–21.
5. Parkin DM (2006) The global health burden of infection-associated cancers in 2002. Int J Cancer 118: 3030–3044.
6. Shi R, Xu S, Zhang H, Ding Y, Sun G, et al. (2008) Prevalence and risk factors for *Helicobacter pylori* infection in Chinese populations. Helicobacter 13: 157–165.
7. Bertuccio P, Chatenoud L, Levi F, Prada D, Ferlay J, et al. (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125: 667–673.
8. Chen J, Bu XL, Wang QY, Hu PJ, Chen MH (2007) Decreasing seroprevalence of *Helicobacter pylori* infection during 1993–2003 in Guangzhou, southern China. Helicobacter 12: 164–169.
9. Kawakami E, Machado RS, Ogata SK, Langner M (2008) Decrease in prevalence of *Helicobacter pylori* infection during a 10-year period in Brazilian children. Arq Gastroenterol 45: 147–151.
10. Tkachenko MA, Zhannat NZ, Erman LV, Blashenkova EL, Isachenko SV, et al. (2007) Dramatic changes in the prevalence of *Helicobacter pylori* infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr 45: 420–432.
11. Lin CS, He PJ, Tsai NM, Li CH, Yang SC, et al. (2010) A potential role for *Helicobacter pylori* heat shock protein 60 in gastric tumorigenesis. Biochem Biophys Res Commun 389: 183–189.
12. Jang S, Jones KR, Olsen CH, Joo YM, Yoo YJ, et al. (2010) Epidemiological link between gastric disease and polymorphisms in VacA and CagA. J Clin Microbiol 48: 559–567.
13. Zhao D, Liu Z, Ding J, Li W, Sun Y, et al. (2010) *Helicobacter pylori* CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J Med Microbiol 59: 259–263.
14. Machado AM, Figueredo C, Seruca R, Rasmussen LJ (2010) *Helicobacter pylori* infection generates genetic instability in gastric cells. Biochim. Biophys Acta 1806: 58–65.
15. Ager P (2006) The aquaporin water channels. Proc Am Thorac Soc 3: 5–13.
16. Magni F, Santo G, Tecozzi D, Soldi M, Bosan N, et al. (2006) Proteomic knowledge of human aquaporins. Proteomics 6: 5637–5649.
17. Hu J, Verkman AS (2006) Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. Faseb J 20: 1892–1894.
29. Zhang DH, Zhou LY, Lin SR, Ding SG, Huang YH, et al. (2009) Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J (Engl) 122: 1759–1763.
30. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, et al. (2011) Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 17: 4421–4428.
31. Uemura N, Okamoto S, Yamamoto S, Yamagishi S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789.
32. Xue FB, Xu YY, Wan Y, Pan BR, Ren J, et al. (2001) Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol 7: 801–804.
33. Wei IC, Wu DC, Yu FJ, Wang JY, Kao CH, et al. (2009) Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol 15: 5465–5471.
34. Yuan JM, Yu MC, Xu WW, Cockburn M, Gao YT, et al. (1999) Helicobacter pylori infection and risk of gastric cancer in Shanghai, China: updated results based upon a locally developed and validated assay and further follow-up of the cohort. Cancer Epidemiol Biomarkers Prev 8: 621–624.
35. Limburg P, Qiao Y, Mark S, Wang G, Perez-Perez G, et al. (2001) Helicobacter pylori seropositivity and subtype-specific gastric cancer risks in Lanzhou, China. J Natl Cancer Inst 93: 226–233.
36. Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, et al. (2007) Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 96: 172–176.
37. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, et al. (2008) Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392–397.
38. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, et al. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187–194.
39. You WC, Brown LM, Zhang L, Li JY, Jin ML, et al. (2006) Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98: 974–983.
40. Ma JI, Zhang L, Brown LM, Li JY, Shen L, et al. (2012) Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 104: 498–492.
41. Yang ZM, Chen WW, Wang YF (2012) Gene expression profiling in gastric mucosa from Helicobacter pylori-infected and uninfected patients undergoing chronic superficial gastritis. PLoS One 7: e33030.